Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P554. Conventional electrochemiluminescence immunoassay method underestimates cortisol suppression in patients with ulcerative colitis treated with oral prednisone
Authors:

F. Manguso1, R. Bennato1, G. Lombardi1, A. Viola2, E. Riccio1, 1AORN A. Cardarelli, UOC Gastroenterology, Napoli, Italy, 2AORN A. Cardarelli, Hematology and Stem Cell Transplantation, Napoli, Italy

P554

Comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis (UC): A systematic review and network meta-analysis

Authors:

A.D. Vickers1, R.R. Mody*2, A. Bergman3, C.S. Ling4, C. Ainsworth1, J. Medjedovic3, M. Smyth5

1RTI Health Solutions, Data Analytics and Design Strategy, Manchester, United Kingdom, 2Takeda Pharmaceuticals International, Inc., Global Outcomes and Epidemiology Research, Deerfield, United States, 3Takeda Pharmaceuticals International GmbH, Global Market Access, Zurich, Switzerland, 4RTI Health Solutions, Market Access and Outcomes Strategy, Manchester, United Kingdom, 5Takeda Development Centre (Europe) Ltd, Global Medical Affairs, London, United Kingdom

P555.

A prospective, controlled, single center pilot study comparing the efficacy of infliximab maintenance therapy (5 mg/kg) every 8 vs. 10 weeks based on successive measurements of fecal calprotectin

Authors:

P. Karatzas, N. Kyriakos, E. Archavlis, X. Tzannetakou, I. Internos, S. Anastasiadis, K. Papamichael, G.J. Mantzaris, Evangelismos Hospital, A' Department of Gastroenterology, Athens, Greece

P555. Conservative approach results in lower colectomy rates in patients with severe ulcerative colitis – data from 70 patients with S3 in the ICURE study
Authors:

D. Sjöberg1, M. Larsson2, A.-l. Nielsen2, L. Holmqvist3, A. Rönnblom4, 1Falu Hospital, Department of Medicine, Falun, Sweden, 2Mälarsjukhuset, Department of Medicine, Eskilstuna, Sweden, 3Akademiska Sjukhuset, Department of Pediatrics, Uppsala, Sweden, 4Akademiska Sjukhuset, Department of Gastroenterology, Uppsala, Sweden

P555

Adherence to medical therapy and follow up in IBD patients

Authors:

M.G. Vettorato*1, A. Rigo2, S. Bellia2, G. Brogiato2, F. Simonetti2, R. D'Incà2, G.C. Sturniolo2

1Azienda Ospedaliera, Department of Surgical, Oncological and Gastroenterological Sciences, Padua, Italy, 2Azienda Ospedaliera di Paodva, Department of Sugery, Oncology and Gastroenterology, Padua, Italy

P556.

Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis

Authors:

M.H. Maillard1, M. Bortolotti2, J.-P. Vader2, C. Mottet3, A. Schoepfer1, J.-J. Gonvers1, B. Burnand2, F. Froehlich4, P. Michetti5, V. Pittet2, 1Lausanne University Hospital, Department of Gastroenterology & Hepatology, Lausanne, Switzerland, 2Institute of Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland, 3Hôpital Neuchâtelois, Service of Gastroenterology, Neuchâtel, Switzerland, 4University Hospital Basel, Division of Gastroenterology & Hepatology, Basel, Switzerland, 5Clinique La Source-Beaulieu, Crohn and Colitis Center, Lausanne, Switzerland

P556. Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohn's disease
Authors:

S. Sazuka1, T. Katsuno1, T. Nakagawa1, K. Saito1, S. Minemura1, A. Oyamada1, D. Maruoka1, T. Matsumura1, M. Arai1, O. Yokosuka1, 1Chiba university hospital, Department of Gastroenterology, Chiba, Japan

P556

A randomized, multicentre, clinical trial to compare prednisone plus granulocyte and monocyte apheresis (GMA) versus prednisone alone for inducing steroid-free remission in patients with steroid dependent Ulcerative Colitis (UC)

Authors:

E. Domènech*1, J. Panés2, J. Hinojosa3, V. Annese4, F. Magro5, R. Lafuente6, on behalf of the ATICCA study of GETECCU7

1Hospital Germans Trias i Pujol, Gastroenterology, Badalona, Spain, 2Hospital Clínic, Gastroenterology, Barcelona, Spain, 3Hospital Manises, Gastroenterology, Valencia, Spain, 4AOU Careggi Hospital, Gastroenterology, Firenze, Italy, 5Centro Hospitalar São João, Gastroenterology, Porto, Portugal, 6Otsuka Pharmaceuticals, Medical Department, Barcelona, Spain, 7Hospital Son Espases, Gastroenterology, Palma de Mallorca, Spain

P557.

Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy

Authors:

A. Balint1, K. Farkas1, É. Pallagi-Kunstár1, G. Terhes2, E. Urbán2, M. Szucs3, T. Nyári3, Z. Bata4, F. Nagy1, Z. Szepes1, P. Miheller5, K. Lorinczy5, P.L. Lakatos6, B. Lovász6, T. Szamosi7, A. Kulcsár8, A. Berényi1, D. Torocsik1, T. Daróczi1, Z. Saródi1, T. Wittmann1, T. Molnár1, 1University of Szeged, First Department of Medicine, Szeged, Hungary, 2University of Szeged, Institute of Clinical Microbiology, Szeged, Hungary, 3University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary, 4University of Szeged, Department of Dermatology and Allergology, Szeged, Hungary, 5Semmelweis University, 2nd Department of Medicine, Budapest, Hungary, 6Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 7National Medical Center, Department of Internal Medicine, Budapest, Hungary, 8Integrated Szent Istvan and Szent László Hospital, Integrated Szent Istvan and Szent László Hospital, Budapest, Hungary

P557. Complex perianal fistula eradication by mucosal advancement flap in IBD patients
Authors:

Z. Serclova1, O. Ryska1, J. Kalvach1, J. Fulik2, 1Central Military Hospital, Department of Surgery, Prague 6, Czech Republic, 2University Hospital Bulovka, Department of Surgery, Prague 8, Czech Republic

P557

Improved mucosal healing during scheduled adalimumab maintenance therapy in patients with Crohn's disease initiated following surgical resection of active lesions

Authors:

A. Yamada*, H. Iwashita, T. Sasaki, M. Katsumata, M. Miyamura, H. Kikuchi, T. Arai, R. Iwasa, R. Furukawa, K. Sono, A. Osamura, K. Nakamura, H. Aoki, Y. Yoshimatsu, Y. Tsuda, K. Takeuchi, N. Takada, Y. Suzuki

Toho University, Sakura Medical Centre, Division of Gastroenterology, Department of Internal Medicine, Sakura, Japan

P558.

Antibodies against infliximab are associated with increased risk of anti-adalimumab antibody development in patients with inflammatory bowel disease

Authors:

M.T. Frederiksen1, M.A. Ainsworth1, J. Brynskov1, O.Ø. Thomsen1, K. Bendtzen2, C. Steenholdt1, 1Herlev University Hospital, Department of Gastroenterology, Herlev, Denmark, 2Rigshospitalet, University Hospital of Copenhagen, Institute for Inflammation Research, Copenhagen, Denmark

P558. Complementary and alternative medicine use in Finnish adolescents with IBD and juvenile idiopathic arthritis
Authors:

P. Nousiainen1,2, K. Aalto2, K.-L. Kolho2, 1Kuopio University Hospital, Department of Pediatrics, Kuopio, Finland, 2Helsinki University Hospital, Children's Hospital, Helsinki, Finland

P558

Twice-daily budesonide rectal foam induces complete mucosal healing in Japanese patients with mild to moderate ulcerative colitis: Results of multicenter, randomized, double-blind, placebo-controlled trial

Authors:

N. Aoyama*1, Y. Suzuki2, H. Nishino3, K. Kobayashi4, F. Hirai5, K. Watanabe6, M. Naganuma7, T. Hibi8

1Aoyama Medical Clinic, GI Endoscopy & IBD Center, Kobe, Japan, 2Sakura Medical Center, Toho University, Department of Internal Medicine, Sakura, Japan, 3Matsushima Clinic, Colo-Proctology Center, Yokohama, Japan, 4Kitasato University, Department of Research and Development Center for New Medical Frontiers, Sagamihara, Japan, 5Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, 6Osaka City General Hospital, Department of Gastroenterology, Osaka, Japan, 7Keio University, Center for Diagnostic and Therapeutic Endoscopy, School of Medicine, Tokyo, Japan, 8Kitasato University, Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Tokyo, Japan

P559.

Anti-tumour necrosis factor therapy improves initial resection rates in Crohn's disease

Authors:

S. Kanmura1, M. Numata1, H. Fujita1, H. Ohi2, M. Kodama3, K. Tokushige4, A. Ido1, 1Kagoshima University Hospital, Gastroenterology, Kagoshima, Japan, 2Imamura Hospital, Gastroenterology, Kagoshima, Japan, 3Miyazaki Medical Center Hospital, Gastroenterology, Miyazaki, Japan, 4Kagoshima Kouseiren Hospital, Gastroenterology, Kagoshima, Japan

P559. Comparison of health care utilization and costs among patients with fistulizing Crohn's disease treated with biologics with or without prior seton procedure
Authors:

D.A. Schwartz1, S.F. Eichner2, J. Lin3, M. Skup2, M. Yang2, P.M. Mulani2, J. Chao2, 1Inflammatory Bowel Disease Center, Vanderbilt University Medical Center, Nashville, TN, United States, 2Abbott Laboratories, Abbott Park, IL, United States, 3Novosys Health, Flemington, NJ, United States

P559

Improving Health Care of Patients with Inflammatory Bowel Diseases (IBD) by Fostering Networking of Physicians - it´s not that easy!

Authors:

B. Bokemeyer*1, J. Langbrandtner2, P. Jessen3, J. Büning4, S. Schreiber5, H. Raspe2, A. Hüppe2

1Gastroenterology Practice Minden, University Hospital Schleswig-Holstein, Department of General Internal Medicine I, Kiel, Germany, Minden, Germany, 2Universität zu Lübeck, Institut für Sozialmedizin und Epidemiologie, Lübeck, Germany, 3Gastroenterology Practice, Gastroenterology, Altenholz, Germany, 4University Hospital Schleswig-Holstein, Campus Lübeck, Medical Department I, Gastroenterology, Lübeck, Germany, 5Christian-Albrechts-Universität, University Hospital Schleswig-Holstein, Department of General Internal Medicine I, Kiel, Germany

P560.

Anti-TNF is safe to stop in the second trimester of pregnancy in IBD women in remission

Authors:

A. de Lima1, Z. Zelinkova1,2, C. van der Ent1, C.J. van der Woude1, 1Erasmus Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands, 2University Hospital, 5th Department of Internal Medicine, Gastroenterology Unit, Bratislava, Slovakia

P560. Comparison of efficacy and tolerance of two maintenance regimens with adalimumab in patients with moderate to severe Crohn's disease
Authors:

J. Filippi1, D. Agrefilo2, E. Fontas3, X. Hébuterne2, 1University of Nice Sophia Antipolis, Gastroenterology Department, Nice, France, 2University of Nice Sophia Antipolis, Gastroenterology Department, Archet 2 Hospital, Nice, France, 3University of Nice Sophia Antipolis, Clinical Research Department, Nice, France

P560

Patients and gastroenterologists' perceptions of treatments in Inflammatory Bowel Disease: Do doctors and patients speak the same language?

Authors:

C. Vaucher1, M.H. Maillard2, M. Timmer1, F. Froehlich3, B. Burnand1, P. Michetti4, V. Pittet*1

1Institute of Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland, 2Lausanne University Hospital, Department of Gastroenterology & Hepatology, Lausanne, Switzerland, 3University Hospital Basel , Division of Gastroenterology & Hepatology, Basel, Switzerland, 4Clinique La Source-Beaulieu, Crohn and Colitis Center, Lausanne, Switzerland